This event has ended. Create your own event → Check it out
This event has ended. Create your own
View analytic
Thursday, September 21 • 11:00am - 1:00pm
SDDN Programming: Scientific Presentations
Feedback form is now closed.
This year the SDDN / SLAS 2017 meeting has the theme "Case Studies in Drug Discovery and Development", and it will showcase several success stories, from academia, biotech, and pharma; opportunities, challenges, solutions and lessons learned will be highlighted. 

This programme is graciously sponsored by Promega

This session will include four, 30-minute presentations. 

Partnering to Face the Challenges of Drug Discovery for the Neglected World
Julio Martin, GlaxoSmithKline

Neglected diseases are understood as those diseases affecting populations in mainly low-income countries. Despite the neglect suffered in terms of funding, research and policy, they are a leading cause of mortality, chronic disability and poverty. Amongst them, Neglected Tropical Diseases (NTDs) are a group of infectious diseases categorized by the particular neglect they have suffered in terms of investment in control measures. NTDs are still lacking effective and safe treatments. Of the 850 new therapeutic products registered in 2000-2011, only 5 were indicated for NTDs, none of them being a new chemical entity (NCE)1. However, the global disease burden caused by NTDs is high. The lack of investment in drug discovery for NTDs has been partially due to the absence of economic incentives. The issue of poverty is central to the nature of NTDs, since these diseases not only are due to poverty but also contribute to it through their socioeconomic impact.
As a response to this unmet medical need of global health, we have adopted a Public-Private-Partnership operative model. In this context, pharma R&D activities are aligned to the main not-for-profit organizations or alliances. Our partnership model is based on three open innovation pillars: open lab (Tres Cantos Open Lab Foundation supports visiting scientists to develop their own research projects working hand to hand with GSK scientists), open source (our early discovery assets are publicly available) and IP pool (we adhere to WIPO principles).
1 B. Pedrique, N. Strub-Wourgaft, C. Some, P. Olliaro, P. Trouiller, N. Ford, B. Pecoul and J. H. Bradol, Lancet Glob. Health, 2013, 1, e371.

The role of venture capital in the drug discovery and development process
Raúl Martín-Ruiz, Ysios Capital 

Start-up companies are, in many cases, the initial source of molecules that might eventually become safe, efficacious and commercially successful pharmaceutical products. Since the life sciences venture capital industry kicked-off back in the late 1970s, it became the main source of funds for financing those innovative companies until they reached the position to be acquired by a bigger player or to become publicly listed in the stock exchange markets.During this talk I will explain how venture capitalists work and which are the reasons between their positive and negative investment decisions. I will review the due diligence process of investment opportunities that they undertake, that covers the whole value chain from science to pricing and reimbursement. Contribution of venture capital to success stories in the biotech sector will also be discussed, as well as creative and innovative business models on top of the traditional ones.

Amelia Martín Uranga, Farmaindustria 

I am going to explain the development of new drugs is currently immersed in a series of important changes that are related, among others, with the following aspects: The general reformulation in investments in R&D; The expiration of patent rights for drugs that have been major sales; The change in focus towards drugs of biological origin;  The ever more widespread trend to outsource part of research. The interest of the pharmaceutical industry in finding new drugs of biological origin is growing, and it needs to do so while maintaining costs are not very high, making attractive the approach of finding products in development in research centers or small start-up companies, in order to reach effective collaboration agreements with them. In this context and within the framework of the Spanish Technological Platform for Innovative Medicines, FARMAINDUSTRIA launched (in the context of open innovation) the Farma-Biotech program in 2011 with the aim of providing the necessary information and promoting potential cooperation agreements between pharmaceutical companies, small Spanish biotechnology companies and research centers, to take advantage in the best way possible of the results of the research conducted in research centers and hospitals, and the positive preclinical findings that were obtained by these small start-ups. The reception by public & private sector has been excellent from the start of the program, and 109 different stakeholders participated in 15 meetings carried out since then.

ASEBIO Drug Discovery Group. A Case study: Harnessing the Power of the Drug Discovery Community in Spain
Arsenio Nueda, Almirall / ASEBIO 

ASEBIO, the Spanish Bioindustry Association, brings together companies, associations, foundations, universities, research and technology centers carrying out biotechnology related activities in Spain. ASEBIO is integrated in EuropaBio (European Bioindustries Association) and is member of the CEOE (Spanish Confederation of Employer’s Organizations) and the SEBBM (Spanish Society for Biochemistry and Molecular Biology). The Drug Discovery Group of ASEBIO was created in June 2016 to promote networking, educational and strategic initiatives based on the expertise and capabilities of ASEBIO members covering the entire drug discovery value chain.

The Group’s activities are articulated around 3 main objectives: (i) Networking and “super-networking” activities through integration and coordination with national and international drug discovery networks, sharing initiatives, information and experiences of common interest. (ii) Educational outreach to the general public and particularly to young students seeking an academic or industrial scientific career in the field of drug discovery. (iii) Offering our capabilities and expertise as a strategic drug discovery bio-industry that can contribute to the risk prevention and emergency response initiatives currently coordinated by the Spanish Health Authorities.

Current activities of the group will be put into context as a case study illustrating the benefits that harnessing the experience, capabilities and networking base of the drug discovery community has both for society and the bio-industry in general.

avatar for Julio Martin

Julio Martin

Head of Kinetoplastid Biology, Director, GSK
I am currently working at the Kinetoplastid Discovery Performance Unit of GSK R&D at Tres Cantos (Spain). Our remit is to discover and develop new chemical entities for the treatment of human diseases caused by kinetoplastid parasites such as Leishmania and Trypanosoma. Our strategy is based on open innovation and collaborative... Read More →
avatar for Raúl Martín-Ruiz

Raúl Martín-Ruiz

Ysios Capital
Raúl Martín-Ruiz is a Principal in Ysios Capital, a leading independent Spanish venture capital firm that provides private equity financing to human healthcare and life sciences companies. Prior to joining Ysios in 2008 he developed his career in Laboratorios Almirall, initially... Read More →
avatar for Arsenio Nueda

Arsenio Nueda

Head, Cell Systems, Almirall, S.A.
I have 18 years experience in the Pharmaceutical Industry and a previous 10 year track record in Academia. I obtained my PhD in 1995 under the direction of Angel Corbí (Hospital de La Princesa, Madrid) working in the characterization of human leukocyte integrin gene promoters. My... Read More →
avatar for Amelia Martín Uranga

Amelia Martín Uranga

Amelia is PHD  in Law, with a thesis on legal protection of biotechnological innovations. She joined FARMAINDUSTRIA in 2006 to manage the Spanish Technological Platform for Innovative Medicines, as Innovative Medicines Initiative mirror. She also is in charge of the coordination... Read More →

Thursday September 21, 2017 11:00am - 1:00pm
Rosales I Courtyard by Marriot Madrid Princesa Hotel